Elif Guler KAZANCİ, Muhammet Furkan KORKMAZ, Vefik ARİCA, Ahmet Ibrahim KURTOGLU

Demographic, clinic, and genetic characteristics in 149 children diagnosed with familial mediterranean fever

Familial Mediterranean fever (FMF) is a hereditary disease characterized by recurrent attacks of fever, peritonitis, pleuritis and/or synovitis. In this study, we retrospec-tively evaluated demographic, clinical findings, and genetic features in 149 children (63 male/86 female) with FMF. The mean age of the patients at the time of diagnosis was 6.44 ± 3.21 years. A positive family history for FMF was present in 26%, and 8% of the patients had consanguinity between the parents. The frequency of family history of FMF was found to be higher in patients diagnosed under 10 years of age (p=0.038). Frequencies of the most frequent symptoms observed in cases during ep-isodes were abdominal pain (95%), fever (68%), and arthralgia/arthritis (23%). Genetic analysis revealed that 16% of the patients had homozygous mutations, 32% had heterozygous mutations, and 38% had compound heterozygous mutations, while no mutations were detected in 21 (14%). There were mutant genes in 218 alleles, the most frequently observed were R202Q (48%), M694V (24%), and E148Q (17%). Patients with non-R202Q compound heterozygous mutation had higher frequency of high fever, CRP (C-reactive protein) levels, and fibrinogen levels during the episodes (p=0.006, p=0.001, and p=0.042, respectively). Thus, our study showed that R202Q mutation appeared to have no significant disease-causing and clinical effects, while mutations at exon 10 were associated with increased severity of symptoms as well as elevated levels of acute phase reactants. Further studies with larger FMF populations may shed more light on the role of these mutations in the pathogenesis of FMF

PDF

___

1. Abraham G. Hereditary Periodic Fever Syndromes. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF (eds): 18th edition. Nelson Textbook of Pediatrics, WB Saunders Co, Philadelphia, 2007;1029-34.

2. Livneh A, Langevitz P, Zemer D, et al. The changing face of Familial Mediterranean fever. Semin Arthritis Rheum. 1996;26:612-27.

3. Kıraz S, Ertenli I, Arici M, et al. Effects of colchicine on inflammatory cytokines and selectins in Familial Mediterranean fever. Clin Exp Rheumatol. 1998;16:721-4.

4. Duzova A, Bakkaloglu A, Besbas N, et al. Role of A- SAA in monitoring subclinical inflammation and in colchicine dosage in Familial Mediterranean fever. Clin Exp Rheumatol. 2003;21:509-14.

5. Lachmann HJ, Sengul B, Yavuzşen TU, et al. Clinical and subclinical inflammation in patients with Familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746-50.

6. Tunca M, Akar S, Önen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84:1-11.

7. Chen X, Fischel-Ghodsian N, Cercek A, et al. Assessment of pyrin gene mutations in Turks with Familial Mediterranean fever (FMF). Human Mutation. 1998;11:456-60.

8. Bakkaloglu A. Familial Mediterranean fever. Pediatric nephrology (Berlin, Germany). 2003;18:853-9.

9. Akin H, Onay H, Turker E, et al. MEFV mutations in patients with Familial Mediterranean fever from the Aegean Region of Turkey. Mol Biol Rep. 2010;37:93-8.

10. Yılmaz R, Ozer S, Ozyurt H, et al. Familial Mediterranean fever gene mutations in the iner northern region of Turkey and genotype-phenotype correlation in children. J Paediatr Child Health. 2009;45:641-5.

11. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659-64.

12. Çağlar A, Özçelik G, Akıncı N. Genotype – phenotype correlation in pediatric patients with Familial Mediterranean Fever. İzmir Dr. Behçet Uz Çocuk Hast. Dergisi. 2018;8:144-50.

13. Sohar E, Gafni J, Pras M et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227-53.

14. Turkish FMF study group. Familial Mediterranean Fever in Turkey: results of a nationwide study. Medicine. 2005;84:1-11.

15. Yavuz S, Selçuk Duru N, Elevli M. Relationship among clinical, laboratory findings, disease severity scores and genetic mutations in patient with Familial Mediterranean fever. Med Bull Haseki. 2018;56:58-64.

16. Soylemezoglu O, Kandur Y, Duzova A, et al. Familial Mediterranean fever with a single MEFV mutation: comparison of rare and common mutations in a Turkish paediatric cohort. Clinical and Experimental Rheumatology. 2015;33:S152-5.

17. Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatology International. 2018;38:67-74.

18. Tchernitchko D, Legendre M, Delahaye A, et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. Clinical Chemistry. 2003;49:1942-5.

19. Ozen S, Besbas N, Bakkaloglu A, et al. Pyrin Q148 mutation and familial Mediterranean fever. QJM: Monthly J Association Physicians. 2002;95:332-3.

20. Oztürk A, Ozçakar B, Ekim M, et al. Is MEFV gene Arg202Gln (605 G>A) A disease-Causing Mutation? Turk J Med Sci. 2008;38:205-8.

21. Yiğit S, Karakuş N, Taşlıyurt T, et al. Significance of MEFV gene R202Q polymorphism in Turkish Familial Mediterranean fever patients. Gene. 2012;506:43-5.

22. Çankaya T, Bora E, Torun Bayram M, et al. Clinical significance of R202Q alteration of MEFV gene in children with Familial Mediterranean fever. Arch Rheumatol. 2015;30:1-6.

23. Giaglis S, Papadopoulos V, Kambas K, et al. MEFV alterations and population genetics analysis in a large cohort of Greek patients with Familial Mediterranean fever. Clin Genet. 2007;71:458–67.